Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH001 and Neoantigen Vaccine-induced T-cells in Advanced Gastrointestinal Cancer
NCT07329894Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PGV002 in gastrointestinal cancer (2 arms), sponsored by Beijing Gaobo Hospital. Primary endpoints: Adverse Events at 12 months and Dose Limiting Toxicity at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
PGV002
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT07329894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07329894.